Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases-Reference-Cited by-同舟云学术

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases

Published:2012-10-23 Issue:5 Volume:119 Page:986-992
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Crocchiolo Roberto,Esterni Benjamin,Castagna Luca,Fürst Sabine,El-Cheikh Jean,Devillier Raynier,Granata Angela,Oudin Claire,Calmels Boris,Chabannon Christian,Bouabdallah Réda,Vey Norbert,Blaise Didier

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference35 articles.

1. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases;Slavin;Blood.,1998

2. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation;Sureda;J Clin Oncol.,2008

3. Review of “minitransplantation”: nonmyeloablative allogeneic hematopoietic stem cell transplantation;Georges;Int J Hematol.,2003

4. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen;Mohty;Blood.,2003

5. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies;Malard;Biol Blood Marrow Transplant.,2011

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

2. Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation;European Journal of Haematology;2024-07-09

3. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies;Blood Reviews;2023-11

4. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation;Transplantology;2023-02-17

5. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors;Transplantation and Cellular Therapy;2022-11